PL2052011T3 - Nakierowany środek terapeutyczny będący dendrymerem polilizynowym - Google Patents

Nakierowany środek terapeutyczny będący dendrymerem polilizynowym

Info

Publication number
PL2052011T3
PL2052011T3 PL07784766T PL07784766T PL2052011T3 PL 2052011 T3 PL2052011 T3 PL 2052011T3 PL 07784766 T PL07784766 T PL 07784766T PL 07784766 T PL07784766 T PL 07784766T PL 2052011 T3 PL2052011 T3 PL 2052011T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
polylysine dendrimer
targeted
targeted polylysine
dendrimer
Prior art date
Application number
PL07784766T
Other languages
English (en)
Inventor
Guy Yeoman Krippner
Charlotte Claire Williams
Brian Devlin Kelly
Scott Andrew Henderson
Zemin Wu
Pasquale Razzino
Original Assignee
Starpharma Pty Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904385A external-priority patent/AU2006904385A0/en
Application filed by Starpharma Pty Limited filed Critical Starpharma Pty Limited
Publication of PL2052011T3 publication Critical patent/PL2052011T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
PL07784766T 2006-08-11 2007-08-10 Nakierowany środek terapeutyczny będący dendrymerem polilizynowym PL2052011T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904385A AU2006904385A0 (en) 2006-08-11 Modified macromolecule 2
EP07784766.3A EP2052011B1 (en) 2006-08-11 2007-08-10 Targeted polylysine dendrimer therapeutic agent
PCT/AU2007/001126 WO2008017125A1 (en) 2006-08-11 2007-08-10 Targeted polylysine dendrimer therapeutic agent

Publications (1)

Publication Number Publication Date
PL2052011T3 true PL2052011T3 (pl) 2021-03-08

Family

ID=39032556

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07784766T PL2052011T3 (pl) 2006-08-11 2007-08-10 Nakierowany środek terapeutyczny będący dendrymerem polilizynowym

Country Status (7)

Country Link
US (1) US8420067B2 (pl)
EP (1) EP2052011B1 (pl)
CN (2) CN101631818B (pl)
DK (1) DK2052011T3 (pl)
ES (1) ES2834916T3 (pl)
PL (1) PL2052011T3 (pl)
WO (1) WO2008017125A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
CA2636599C (en) * 2006-01-20 2014-07-15 Starpharma Pty Limited Modified macromolecule
FR2955111B1 (fr) * 2010-01-12 2013-05-31 Biomerieux Sa Procede de preparation de composes polybiotinyles
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
IN2014DN00101A (pl) * 2011-06-06 2015-05-15 Starpharma Pty Ltd
WO2014190257A2 (en) 2013-05-23 2014-11-27 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
US10730999B2 (en) 2014-06-06 2020-08-04 Starpharma Pty Ltd Dendrimer-drug conjugates
CN105833791B (zh) * 2016-03-30 2017-10-24 大连理工大学 一种含有邻硝基苄酯光降解基团的表面活性剂及其制备方法
CN110114075B (zh) 2016-11-09 2024-01-12 俄亥俄州国家创新基金会 含有二硫化物的细胞穿透肽及其制备和使用方法
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
WO2018098282A2 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
EP3562512B1 (en) * 2016-11-28 2024-11-27 Indian Institute Of Technology, Delhi A formulation for stabilizing bio-therapeutics
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
CN112424178B (zh) 2018-07-19 2025-01-28 星法马私人有限公司 治疗性树状聚体
FI129022B (en) 2019-09-10 2021-05-14 Aabo Akademi Univ Polymer and composition made from a renewable source
CN110742856B (zh) * 2019-10-17 2020-11-10 南京工业大学 靶向递送并消耗大量h2o2的同时释放co的纳米凝胶药物载体、制备方法及其应用
CN114349958A (zh) * 2022-01-24 2022-04-15 西南石油大学 一种超支化聚赖氨酸叔胺插层抑制剂的合成及水基钻井液
CN121079342A (zh) * 2023-05-08 2025-12-05 上海森辉医药有限公司 抗真菌药的载药大分子及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
EP0969873B1 (en) * 1997-03-27 2006-06-07 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
EP0884327B1 (en) * 1997-06-11 2001-03-14 The School Of Pharmacy, University Of London Dendritic lysine-based polypeptides for targeted drug delivery
DE19728954C1 (de) * 1997-06-30 1999-04-22 Schering Ag Saccharid-Konjugate, diese enthaltende pharmazeutische Mittel, Verfahren zu ihrer Herstellung und ihre Verwendung
AUPQ288499A0 (en) * 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
AUPR412801A0 (en) * 2001-03-30 2001-05-03 Starpharma Limited Agent for the prevention and treatment of sexually transmitted disease s - I
AU2003225636A1 (en) 2002-03-05 2003-09-22 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
GB0209022D0 (en) * 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
US7985424B2 (en) * 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
CA2626865C (en) * 2005-10-25 2014-12-30 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry

Also Published As

Publication number Publication date
CN101516969A (zh) 2009-08-26
CN101631818B (zh) 2013-02-06
ES2834916T3 (es) 2021-06-21
US20100292148A1 (en) 2010-11-18
EP2052011A1 (en) 2009-04-29
CN101516969B (zh) 2013-07-03
EP2052011B1 (en) 2020-11-04
US8420067B2 (en) 2013-04-16
DK2052011T3 (da) 2020-12-07
EP2052011A4 (en) 2012-08-22
WO2008017125A1 (en) 2008-02-14
CN101631818A (zh) 2010-01-20

Similar Documents

Publication Publication Date Title
PL2052011T3 (pl) Nakierowany środek terapeutyczny będący dendrymerem polilizynowym
EP2076557A4 (en) POLYLYSINE DENDRIMER CONTRAST AGENT
GB0609492D0 (en) Therapeutic agents
IL196559A0 (en) Combination therapy
ZA200807253B (en) Targeted mobile device advertisements
ZA200902823B (en) Oligoribonucleotides and uses thereof
GB0608928D0 (en) Therapeutic agents
GB0601962D0 (en) Therapeutic agents
IL192996A0 (en) Targeted mobile device advertisements
IL196556A0 (en) Combination therapy
IL205970A0 (en) Targeted radiotherapy
EP2054061A4 (en) COMBINATION THERAPY
IL197235A0 (en) Therapeutic compositions
GB0616214D0 (en) Therapeutic Agents
ZA200902203B (en) Combination therapy
TWI371192B (en) Verified distance ranging
GB0611152D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
EP2047804A4 (en) ultrasonograph
GB0606660D0 (en) Targeted Therapy
GB0622195D0 (en) Therapeutic agents
GB0601818D0 (en) Therapeutic agent
GB0706648D0 (en) Targeting device